163 related articles for article (PubMed ID: 9868032)
41. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
[TBL] [Abstract][Full Text] [Related]
42. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
43. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
[TBL] [Abstract][Full Text] [Related]
44. [Utility of dopa decarboxylase as a novel marker for the detection of peritoneal micro-metastases of gastric cancer with realtime RT-PCR].
Sakakura C; Takemura M; Miyagawa K; Fukuda K; Shimomura K; Kin S; Nakase Y; Kuriu Y; Nakashima S; Yoshikawa T; Ueda Y; Fujiyama J; Sonoyama T; Okazaki Y; Hayashizaki Y; Hagiwara A; Yamagishi H
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1906-8. PubMed ID: 15553755
[TBL] [Abstract][Full Text] [Related]
45. Paracentesis. The importance of optimal ascitic fluid analysis.
Bac DJ; Siersema PD; Wilson JH
Neth J Med; 1993 Oct; 43(3-4):147-55. PubMed ID: 8302393
[TBL] [Abstract][Full Text] [Related]
46. Biochemical pattern of the ascitic fluid in liver cirrhosis and in neoplastic diseases.
Boca M; Hanták I; Mikulecký M; Ondrejka P
Gastroenterol J; 1991; 51(3-4):136-7. PubMed ID: 1811658
[TBL] [Abstract][Full Text] [Related]
47. Role of cancer antigen-125 from pleural & ascitic fluid samples in non malignant conditions.
Kalantri Y; Naik G; Joshi SP; Jain A; Phatak S; Chavan R; Hemvani N; Chitnis DS
Indian J Med Res; 2007 Jan; 125(1):25-30. PubMed ID: 17332654
[TBL] [Abstract][Full Text] [Related]
48. Flow cytometry in the diagnosis of peritoneal carcinomatosis.
Both CT; de Mattos AA; Neumann J; Reis MD
Am J Gastroenterol; 2001 May; 96(5):1605-9. PubMed ID: 11374707
[TBL] [Abstract][Full Text] [Related]
49. [Ascites].
Mathurin P
Rev Prat; 2010 Mar; 60(3):397-8. PubMed ID: 20402139
[No Abstract] [Full Text] [Related]
50. Ascitic fluid lactoferrin for diagnosis of spontaneous bacterial peritonitis.
Parsi MA; Saadeh SN; Zein NN; Davis GL; Lopez R; Boone J; Lepe MR; Guo L; Ashfaq M; Klintmalm G; McCullough AJ
Gastroenterology; 2008 Sep; 135(3):803-7. PubMed ID: 18590731
[TBL] [Abstract][Full Text] [Related]
51. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
52. [Hemoperitoneum--how to proceed?].
Stähelin B; Schaad HJ
Praxis (Bern 1994); 1999 Feb; 88(9):379-82. PubMed ID: 10191686
[TBL] [Abstract][Full Text] [Related]
53. [Expression of heparanase mRNA in ascitic cells is not a good marker in differential diagnosis of malignancies].
Cai YG; Fang DC; Yang SM; Luo YH; Chen L; Yang MH; Wang DX
Zhonghua Gan Zang Bing Za Zhi; 2005 May; 13(5):390-1. PubMed ID: 15918984
[No Abstract] [Full Text] [Related]
54. Bradykinin in the ascitic fluid of patients with liver cirrhosis.
Cugno M; Salerno F; Nussberger J; Bottasso B; Lorenzano E; Agostoni A
Clin Sci (Lond); 2001 Dec; 101(6):651-7. PubMed ID: 11724653
[TBL] [Abstract][Full Text] [Related]
55. [Usefulness of cholinesterase determination in ascitic fluid in the differential diagnosis of ascites].
Vázquez Rodríguez de Alba J; Ena Muñoz J; Such Ronda J; Almenar Bonet MV; Graells Ferrer ML
An Med Interna; 2000 Jul; 17(7):351-5. PubMed ID: 10981331
[TBL] [Abstract][Full Text] [Related]
56. [Ascites. Diagnostic orientation].
Christidis C; Ganne-Carrié N; Beaugrand M
Rev Prat; 1996 Jun; 46(11):1419-22. PubMed ID: 8794629
[No Abstract] [Full Text] [Related]
57. Free fatty acid analysis in ascitic fluid improves diagnosis in malignant abdominal tumors.
Greco AV; Mingrone G; Gasbarrini G
Clin Chim Acta; 1995 Jul; 239(1):13-22. PubMed ID: 7586583
[TBL] [Abstract][Full Text] [Related]
58. [Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Iizuka R; Takahashi S; Kakihara N; Matsumura H; Takenaka A
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1251-3. PubMed ID: 12146009
[No Abstract] [Full Text] [Related]
59. Erythrocyte-binding polyamine as a tumor growth marker for human hepatocellular carcinoma.
Nishiguchi S; Tamori A; Koh N; Fujimoto S; Takeda T; Shiomi S; Oka H; Yano Y; Otani S; Kuroki T
Hepatogastroenterology; 2002; 49(44):504-7. PubMed ID: 11995483
[TBL] [Abstract][Full Text] [Related]
60. Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites.
Liu F; Kong X; Dou Q; Ye J; Xu D; Shang H; Xu K; Song Y
Ann Hepatol; 2014; 13(3):357-63. PubMed ID: 24756011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
